Atellica IM free PSA II (fPSAII)
Siemens Healthcare Diagnostics, Inc. · Decision date May 11, 2026
What did the FDA approve?
FDA records P250026 as an original PMA application. The recorded decision is approval, dated May 11, 2026.
FDA approval order statement
Approval for the Atellica IM free PSA II (fPSAII):The Atellica IM free PSA II (fPSAII) assay is for in vitro diagnostic use in the quantitative measurement of free prostate-specific antigen (fPSA) in human serum and plasma (lithium heparin and EDTA) using the Atellica IM Analyzer. The Atellica IM fPSAII assay is intended to be used in conjunction with the Atellica IM total PSA II (tPSAII) assay in men aged 50 years and older with total prostate-specific antigen (PSA) values between 4 ng/mL (µg/L) and 10 ng/mL (µg/L) and a digital rectal examination (DRE) non-suspicious for cancer to determine the percent free PSA value. The percent free PSA value can be used as an aid in discriminating between prostate cancer and benign prostatic disease. A prostate biopsy is required for the diagnosis of prostate cancer.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Immunology
- Decision date
- May 11, 2026
Regulatory record facts
- Identifier
- P250026
- Regulatory pathway
- Premarket approval application
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- MTG
- Decision code
- APPR
- Decision date
- May 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions.
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Product code
- MTG
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250026 received
Application receipt date recorded by FDA.
P250026 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250026. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MTG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IMMULITE Systems Free PSAP060005/S027 | Siemens Medical Solutions Diagnostics Limited | PMA supplement | Sep 22, 2026 | FDA |
IMMULITE Systems Free PSAP060005/S026 | Siemens Medical Solutions Diagnostics Limited | PMA supplement | Aug 20, 2026 | FDA |
IMMULITE 2000 Free PSAP060005/S025 | Siemens Medical Solutions Diagnostics Limited | PMA supplement | Jul 27, 2026 | FDA |
IMMULITE 2000 Free PSAP060005/S024 | Siemens Medical Solutions Diagnostics Limited | PMA supplement | Apr 21, 2026 | FDA |
| ABBOTT LABORATORIES | PMA supplement | Feb 12, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- 511 Benedict Ave., Tarrytown, NY, 10591
Sources and methodology
- Original FDA record: P250026
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



